News | April 06, 2022
Revenue growth to moderate, non-Covid-19 revenue to drive profitability
Ind-Ra maintains a neutral outlook for healthcare in FY23
Ind-Ra maintains a neutral outlook for healthcare in FY23
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
BioFluidica LiquidScan harnesses the power of microfluidics
Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process
The kidney swap transplant procedure provides a solution to a critical shortage of compatible kidneys for patients suffering from kidney failures in India
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
Pilots to be launched across multiple locations in India.
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Subscribe To Our Newsletter & Stay Updated
